These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 22402069)

  • 1. Nutritional therapy to prevent dyslipidemia in patients starting antiretroviral therapy for human immunodeficiency virus.
    Stein JH
    J Am Coll Cardiol; 2012 Mar; 59(11):989-90. PubMed ID: 22402069
    [No Abstract]   [Full Text] [Related]  

  • 2. Dietary intervention prevents dyslipidemia associated with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected individuals: a randomized trial.
    Lazzaretti RK; Kuhmmer R; Sprinz E; Polanczyk CA; Ribeiro JP
    J Am Coll Cardiol; 2012 Mar; 59(11):979-88. PubMed ID: 22402068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dyslipidemia related to antiretroviral therapy.
    Estrada V; Portilla J
    AIDS Rev; 2011; 13(1):49-56. PubMed ID: 21412389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV and highly active antiretroviral therapy: dyslipidemia, metabolic aberrations, and cardiovascular risk.
    Zou W; Berglund L
    Prev Cardiol; 2007; 10(2):96-103; quiz 104-5. PubMed ID: 17392622
    [No Abstract]   [Full Text] [Related]  

  • 5. [Is dyslipidemia a risk factor in patients treated with antiretroviral drugs?].
    Soska V
    Vnitr Lek; 2008 Feb; 54(2):135-6. PubMed ID: 23687702
    [No Abstract]   [Full Text] [Related]  

  • 6. Current therapy for human immunodeficiency virus infection and acquired immunodeficiency syndrome.
    Honda M; Oka S
    Int J Hematol; 2006 Jul; 84(1):18-22. PubMed ID: 16867897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Highly active antiretroviral therapy and dyslipidemia in people living with HIV/AIDS in Fako Division, South West Region of Cameroon.
    Nsagha DS; Weledji EP; Assob NJ; Njunda LA; Tanue EA; Kibu OD; Ayima CW; Ngowe MN
    BMC Cardiovasc Disord; 2015 Aug; 15():95. PubMed ID: 26315756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiretroviral and statin drug-drug interactions.
    Ray GM
    Cardiol Rev; 2009; 17(1):44-7. PubMed ID: 19092370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dyslipidemia in AIDS patients on highly active antiretroviral therapy.
    Nery MW; Martelli CM; Turchi MD
    Braz J Infect Dis; 2011; 15(2):151-5. PubMed ID: 21503402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of association between dyslipidemia and insulin resistance in HIV-infected persons treated with highly active antiretroviral therapy.
    Swanson B; Keithley JK; Zeller JM; Sha BE
    Nutrition; 2004; 20(11-12):1022-5. PubMed ID: 15561494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adipokine profiles and lipodystrophy in HIV-infected children during the first 4 years on highly active antiretroviral therapy.
    Resino S; Micheloud D; Lorente R; Bellon JM; Navarro ML; Munoz-Fernandez MA
    HIV Med; 2011 Jan; 12(1):54-60. PubMed ID: 20497248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dyslipidemia in HIV Infected Children Receiving Highly Active Antiretroviral Therapy.
    Mandal A; Mukherjee A; Lakshmy R; Kabra SK; Lodha R
    Indian J Pediatr; 2016 Mar; 83(3):226-31. PubMed ID: 26334860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyperlactatemia and human immunodeficiency virus infection: lessons from the era of antiretroviral monotherapy.
    Chariot P; Bourokba N; Monnet I; Gherardi R
    Antimicrob Agents Chemother; 2002 Nov; 46(11):3683. PubMed ID: 12384392
    [No Abstract]   [Full Text] [Related]  

  • 14. Systemic and cell-specific mechanisms of vasculopathy induced by human immunodeficiency virus and highly active antiretroviral therapy.
    Haser GC; Sumpio B
    J Vasc Surg; 2017 Mar; 65(3):849-859. PubMed ID: 26994951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Giant cell myocarditis associated with multiple autoimmune disorders following highly active antiretroviral therapy for human immunodeficiency virus type 1 infection.
    Ikeda Y; Inomata T; Nishinarita R; Oikawa J; Kishihara J; Koitabashi T; Wada T; Takeuchi I; Ako J
    Int J Cardiol; 2016 Mar; 206():79-81. PubMed ID: 26780680
    [No Abstract]   [Full Text] [Related]  

  • 16. Safety and efficacy of simvastatin for the treatment of dyslipidemia in human immunodeficiency virus-infected patients receiving efavirenz-based highly active antiretroviral therapy.
    Rahman AP; Eaton SA; Nguyen ST; Bain AM; Payne KD; Bedimo R; Busti AJ
    Pharmacotherapy; 2008 Jul; 28(7):913-9. PubMed ID: 18576906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treating antiretroviral-induced dyslipidemia in HIV-infected adults.
    Scordo KA
    Nurse Pract; 2010 Jul; 35(7):32-7; quiz 37-8. PubMed ID: 20555242
    [No Abstract]   [Full Text] [Related]  

  • 18. Serum lipid profile in highly active antiretroviral therapy-naïve HIV-infected patients in Cameroon: a case-control study.
    Nguemaïm NF; Mbuagbaw J; Nkoa T; Alemnji G; Této G; Fanhi TC; Asonganyi T; Samé-Ekobo A
    HIV Med; 2010 Jul; 11(6):353-9. PubMed ID: 20345886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emergence of systemic lupus erythematosus after initiation of highly active antiretroviral therapy for human immunodeficiency virus infection.
    Diri E; Lipsky PE; Berggren RE
    J Rheumatol; 2000 Nov; 27(11):2711-4. PubMed ID: 11093459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Serum leptin and adiponectin concentrations in patients infected with human immunodeficiency virus type 1 (HIV-1) on antiretroviral therapy].
    Leszczyszyn-Pynka M; Pynka S; Boroń-Kaczmarska A; Pilarska K
    Endokrynol Pol; 2005; 56(1):19-24. PubMed ID: 16335669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.